Tyra Biosciences Director Rehan Buys 972 Shares

What Happened
Director Rehan acquired 971.894 shares of Tyra Biosciences (TYRA) in an open-market purchase (Form 4 code P). The filing reports a weighted-average price of $20.58 per share for a total cash outlay of approximately $20,000. This was a purchase (buy), which investors often view as a positive signal, though the filing does not state the insider's motives.

Key Details

• Transaction date: 2026-09-09.
• Transaction type: Open-market purchase (SEC Form 4 code P).
• Shares acquired: 971.894 shares.
• Price: weighted average $20.58; underlying transaction prices ranged from $20.5550 to $20.6488 (see footnote).
• Total value: approximately $20,000.
• Shares owned after transaction: not disclosed in the provided filing.
• Footnote: The reported price is a weighted average; the reporting person will provide a breakdown of shares purchased at each price upon request (Footnote F1).
• Filing timeliness: Form 4 filed 2026-09-11 for a 2026-09-09 transaction — filed within the standard two-business-day window.

Context
This was a modest-dollar open-market purchase rather than an option exercise, grant, or gift. Small purchases like this can be of interest to retail investors as a sign of insider buying, but the filing contains no information on intent or future plans.